Shareholders of Gaithersburg-based BioVeris Corp. approves

BioVeris Corp.'s shareholders voted Monday to approve the company's $600 million acquisition by Basel, Switzerland-based Roche Holding AG. Roche, the world's biggest maker of diagnostic tests, agreed to pay $21.50 a share in cash -- a total of $600 million -- to acquire Gaithersburg-based BioVeris, a manufacturer of diagnostic equipment.

As a result, BioVeris' stock has been delisted from the Nasdaq Global Market. BioVeris Chief Executive Officer Samuel Wohlstadter, 64, stands to gain $113.2 million from the transaction.

Copyright 2007 Dolan Media Newswires
Provided by ProQuest Information and Learning Company. All rights Reserved.